Translate Bio Granted US Patent for Cystic Fibrosis mRNA Therapy Encoding CFTR
Summary
Translate Bio, Inc. has been granted US Patent 12611442B2 on April 28, 2026, covering mRNA compositions encoding engineered CFTR proteins for treating cystic fibrosis. The patent application (No. 17761893) was originally filed on September 17, 2020, and contains 10 claims. The grant becomes publicly accessible and enforceable against third parties.
“The present invention provides, among other things, improved methods and pharmaceutical compositions for treating cystic fibrosis based on codon optimized mRNA encoding an engineered or mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein.”
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
USPTO issued patent 12611442B2 to Translate Bio on April 28, 2026, covering methods and compositions for treating cystic fibrosis using codon-optimized mRNA encoding engineered CFTR proteins. The patent strengthens Translate Bio's intellectual property position in the mRNA therapeutics space for cystic fibrosis treatment. Third parties developing similar mRNA-based CFTR programs should assess potential licensing needs.
Affected parties include pharmaceutical and biotechnology companies engaged in mRNA-based cystic fibrosis research or development programs, who may need to evaluate freedom-to-operate considerations regarding Translate Bio's newly granted claims.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
mRNA encoding engineered CFTR
Grant US12611442B2 Kind: B2 Apr 28, 2026
Assignee
TRANSLATE BIO, INC.
Inventors
Richard Wooster, Frank DeRosa, Lianne Boeglin, Priyaanka Nanduri, Anusha Dias, Khang Anh Tran
Abstract
The present invention provides, among other things, improved methods and pharmaceutical compositions for treating cystic fibrosis based on codon optimized mRNA encoding an engineered or mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein.
CPC Classifications
A61K 38/177 A61P 11/00 C12N 15/00
Filing Date
2020-09-17
Application No.
17761893
Claims
10
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.